Literature DB >> 21936166

[Generic drugs in Brazil: impacts of public policies upon the national industry].

Cristiane Quental1, Jussanã Cristina de Abreu, José Vitor Bomtempo, Carlos Augusto Grabois Gadelha.   

Abstract

This paper echoes recent works of Abrasco, Gadelha and Guimarães emphasizing the need for a better integration between health policies and industrial development and innovation policies as the only way to keep the economic benefits generated by health expenditures in the country instead of letting them escape through imports and threaten the continuity of the social policy by growing trade deficits. Although presenting the generic drug policy as a successful case in integrating social policies aimed at a better access to quality drugs for the population with economic policies aimed at industrial development, this paper discusses the impacts and limitations of the referred policy in a dialog with Abreu's analysis of industrial competitiveness in the Brazilian generics industry.

Mesh:

Substances:

Year:  2008        PMID: 21936166     DOI: 10.1590/s1413-81232008000700011

Source DB:  PubMed          Journal:  Cien Saude Colet        ISSN: 1413-8123


  2 in total

1.  Use of generic medicines by the Brazilian population: an evaluation of PNAUM 2014.

Authors:  Andréa Dâmaso Bertoldi; Paulo Sergio Dourado Arrais; Noemia Urruth Leão Tavares; Luiz Roberto Ramos; Vera Lucia Luiza; Sotero Serrate Mengue; Tatiane da Silva Dal-Pizzol; Mareni Rocha Farias; Maria Auxiliadora Oliveira
Journal:  Rev Saude Publica       Date:  2016-12       Impact factor: 2.106

Review 2.  Paving New Roads Towards Biodiversity-Based Drug Development in Brazil: Lessons from the Past and Future Perspectives.

Authors:  Fernão Castro Braga
Journal:  Rev Bras Farmacogn       Date:  2021-09-17       Impact factor: 2.010

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.